SE9702086D0 - Anti-cancer drug delivery to solid tumors - Google Patents

Anti-cancer drug delivery to solid tumors

Info

Publication number
SE9702086D0
SE9702086D0 SE9702086A SE9702086A SE9702086D0 SE 9702086 D0 SE9702086 D0 SE 9702086D0 SE 9702086 A SE9702086 A SE 9702086A SE 9702086 A SE9702086 A SE 9702086A SE 9702086 D0 SE9702086 D0 SE 9702086D0
Authority
SE
Sweden
Prior art keywords
solid tumors
agents
agent
camp
primer
Prior art date
Application number
SE9702086A
Other languages
English (en)
Swedish (sv)
Inventor
Kristofer Rubin
Mats Sjoequist
Rolf Reed
Original Assignee
Biophausia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophausia Ab filed Critical Biophausia Ab
Priority to SE9702086A priority Critical patent/SE9702086D0/xx
Publication of SE9702086D0 publication Critical patent/SE9702086D0/xx
Priority to DK98930728T priority patent/DK0977559T3/da
Priority to CA002292699A priority patent/CA2292699A1/en
Priority to DE69808270T priority patent/DE69808270T2/de
Priority to US09/424,256 priority patent/US6303660B1/en
Priority to PCT/EP1998/003078 priority patent/WO1998055112A1/en
Priority to AT98930728T priority patent/ATE224706T1/de
Priority to EP98930728A priority patent/EP0977559B1/de
Priority to JP50141799A priority patent/JP2002502399A/ja
Priority to AU81061/98A priority patent/AU733882B2/en
Priority to PT98930728T priority patent/PT977559E/pt
Priority to ES98930728T priority patent/ES2184289T3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9702086A 1997-06-02 1997-06-02 Anti-cancer drug delivery to solid tumors SE9702086D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9702086A SE9702086D0 (sv) 1997-06-02 1997-06-02 Anti-cancer drug delivery to solid tumors
ES98930728T ES2184289T3 (es) 1997-06-02 1998-05-26 Suministracion de un agente anticanceroso mejorado a tumores solidos como primer componente.
US09/424,256 US6303660B1 (en) 1997-06-02 1998-05-26 Enhanced anti-cancer agent delivery to solid tumors by primer compounds
CA002292699A CA2292699A1 (en) 1997-06-02 1998-05-26 Enhanced anti-cancer agent delivery to solid tumors by primer compounds
DE69808270T DE69808270T2 (de) 1997-06-02 1998-05-26 Verbesserte darreichung von antikrebsmittel an feste tumore mittels primer-verbindungen
DK98930728T DK0977559T3 (da) 1997-06-02 1998-05-26 Forøget tilførsel af anti-cancer middel til faste tumorer ved primerforbindelser
PCT/EP1998/003078 WO1998055112A1 (en) 1997-06-02 1998-05-26 Enhanced anti-cancer agent delivery to solid tumors by primer compounds
AT98930728T ATE224706T1 (de) 1997-06-02 1998-05-26 Verbesserte darreichung von antikrebsmittel an feste tumore mittels primer-verbindungen
EP98930728A EP0977559B1 (de) 1997-06-02 1998-05-26 Verbesserte darreichung von antikrebsmittel an feste tumore mittels primer-verbindungen
JP50141799A JP2002502399A (ja) 1997-06-02 1998-05-26 プライマー化合物による抗癌剤の固形癌への増強された送達
AU81061/98A AU733882B2 (en) 1997-06-02 1998-05-26 Enhanced anti-cancer agent delivery to solid tumors by primer compounds
PT98930728T PT977559E (pt) 1997-06-02 1998-05-26 Entrega melhorada por compostos primarios de agente anticanceroso a tumores solidos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702086A SE9702086D0 (sv) 1997-06-02 1997-06-02 Anti-cancer drug delivery to solid tumors

Publications (1)

Publication Number Publication Date
SE9702086D0 true SE9702086D0 (sv) 1997-06-02

Family

ID=20407206

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702086A SE9702086D0 (sv) 1997-06-02 1997-06-02 Anti-cancer drug delivery to solid tumors

Country Status (12)

Country Link
US (1) US6303660B1 (de)
EP (1) EP0977559B1 (de)
JP (1) JP2002502399A (de)
AT (1) ATE224706T1 (de)
AU (1) AU733882B2 (de)
CA (1) CA2292699A1 (de)
DE (1) DE69808270T2 (de)
DK (1) DK0977559T3 (de)
ES (1) ES2184289T3 (de)
PT (1) PT977559E (de)
SE (1) SE9702086D0 (de)
WO (1) WO1998055112A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630120B1 (en) * 1999-03-08 2003-10-07 Alkermes, Inc. Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
IL160928A0 (en) * 2001-10-19 2004-08-31 Maxim Pharm Inc Use of histamine to treat liver disease
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
JP2015144904A (ja) * 2015-04-20 2015-08-13 佐藤　洋 位置制御システム
AU2017382294A1 (en) * 2016-12-22 2019-08-01 Abbvie Inc. Compositions and methods of enhancing or augmenting type I IFN production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
US4654366A (en) * 1986-02-14 1987-03-31 E. R. Squibb & Sons, Inc. Hydroxamic acids of 7-oxabicyclo[2.2.1]heptane substituted ethers useful as anti-thrombotic agents
US4654367A (en) * 1986-02-14 1987-03-31 E. R. Squibb & Sons, Inc. Hydroxamic acids of 7-oxabicycloheptane substituted ethers useful as anti-allergy and anti-inflammation agents

Also Published As

Publication number Publication date
AU8106198A (en) 1998-12-21
DK0977559T3 (da) 2003-01-27
US6303660B1 (en) 2001-10-16
DE69808270D1 (de) 2002-10-31
PT977559E (pt) 2003-02-28
CA2292699A1 (en) 1998-12-10
WO1998055112A1 (en) 1998-12-10
AU733882B2 (en) 2001-05-31
ATE224706T1 (de) 2002-10-15
JP2002502399A (ja) 2002-01-22
EP0977559A1 (de) 2000-02-09
ES2184289T3 (es) 2003-04-01
DE69808270T2 (de) 2003-05-22
EP0977559B1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
Ishikawa et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
PL347671A1 (en) Compounds and compositions for delivering active agents
PL377146A1 (pl) Cytokiny ochronne dla tkanek do ochrony, odnowy i wzmacniania reaktywnych komórek, tkanek i narządów
WO2005086798A3 (en) Improved interleukin-2 muteins
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2004003176A3 (en) Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
EP0993831A3 (de) Komponente und Zusammensetzungen zur Verabreichung von Wirkstoffen
JPS6036422A (ja) １−ドデシルアザシクロヘプタン−２−オンを含有する浸透局所製薬組成物
DE60202278D1 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
PT1146861E (pt) Formulacoes de particulas de hidrogel
CA2317582A1 (en) A drug dosage form based on the teorell-meyer gradient
Lukashev et al. From ‘Hellstrom Paradox–to anti-adenosinergic cancer immunotherapy
PT977559E (pt) Entrega melhorada por compostos primarios de agente anticanceroso a tumores solidos
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
EP1064966A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
Raghunathan et al. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice
Poplin et al. Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
AU2204701A (en) Formulations of adenosine a1 agonists
IL135872A0 (en) Use of histamine for elevating blood histamine levels
Sumiyoshi et al. Heterogenicity of ornithine decarboxylase during mouse colon carcinogenesis and in human colon tumors